CA2362918A1 - Procedes et compositions pour le traitement de la dyserection - Google Patents

Procedes et compositions pour le traitement de la dyserection Download PDF

Info

Publication number
CA2362918A1
CA2362918A1 CA002362918A CA2362918A CA2362918A1 CA 2362918 A1 CA2362918 A1 CA 2362918A1 CA 002362918 A CA002362918 A CA 002362918A CA 2362918 A CA2362918 A CA 2362918A CA 2362918 A1 CA2362918 A1 CA 2362918A1
Authority
CA
Canada
Prior art keywords
receptor
melanocortin
alpha
inhibitor
agonist
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002362918A
Other languages
English (en)
Inventor
Elizabeth Stoner
Joanne Waldstreicher
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck and Co Inc
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2362918A1 publication Critical patent/CA2362918A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/502—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with carbocyclic ring systems, e.g. cinnoline, phthalazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Reproductive Health (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gynecology & Obstetrics (AREA)
  • Endocrinology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La présente invention porte sur un procédé de traitement de la dysérection affectant l'homme ou la femme. Ce procédé consiste à administrer une quantité thérapeutiquement efficace d'un agoniste du récepteur de la mélanocortine en combinaison avec une quantité thérapeutiquement efficace d'un inhibiteur de phosphodiestérase spécifique de GMP cyclique ou d'un antagoniste du récepteur alpha adrénergique. Cette invention porte également sur les compositions pharmaceutiques utiles dans les procédés de l'invention, ainsi que sur un procédé de fabrication d'un médicament utile pour traiter la dysérection.
CA002362918A 1999-03-08 2000-03-03 Procedes et compositions pour le traitement de la dyserection Abandoned CA2362918A1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US12324499P 1999-03-08 1999-03-08
US60/123,244 1999-03-08
PCT/US2000/005711 WO2000053148A2 (fr) 1999-03-08 2000-03-03 Procedes et compositions pour le traitement de la dyserection

Publications (1)

Publication Number Publication Date
CA2362918A1 true CA2362918A1 (fr) 2000-09-14

Family

ID=22407530

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002362918A Abandoned CA2362918A1 (fr) 1999-03-08 2000-03-03 Procedes et compositions pour le traitement de la dyserection

Country Status (4)

Country Link
EP (1) EP1161255A4 (fr)
AU (1) AU3724400A (fr)
CA (1) CA2362918A1 (fr)
WO (1) WO2000053148A2 (fr)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6548490B1 (en) 1997-10-28 2003-04-15 Vivus, Inc. Transmucosal administration of phosphodiesterase inhibitors for the treatment of erectile dysfunction
US6403597B1 (en) 1997-10-28 2002-06-11 Vivus, Inc. Administration of phosphodiesterase inhibitors for the treatment of premature ejaculation
ES2187234A1 (es) * 1999-04-30 2003-05-16 Lilly Icos Llc Forma de dosificacion oral para tratar la disfuncion sexual.
US6943166B1 (en) 1999-04-30 2005-09-13 Lilly Icos Llc. Compositions comprising phosphodiesterase inhabitors for the treatment of sexual disfunction
US7235625B2 (en) * 1999-06-29 2007-06-26 Palatin Technologies, Inc. Multiple agent therapy for sexual dysfunction
US7176279B2 (en) 2000-06-28 2007-02-13 Palatin Technologies, Inc. Cyclic peptide compositions and methods for treatment of sexual dysfunction
EA004872B1 (ru) 1999-08-03 2004-08-26 ЛИЛЛИ АЙКОС эЛ-эЛ-Си β-КАРБОЛИНОВЫЕ ФАРМАЦЕВТИЧЕСКИЕ КОМПОЗИЦИИ
TWI265925B (en) 1999-10-11 2006-11-11 Pfizer Pyrazolo[4,3-d]pyrimidin-7-ones useful in inhibiting type 5 cyclic guanosine 3',5'-monophosphate phosphodiesterases(cGMP PDE5), process and intermediates for their preparation, their uses and composition comprising them
AU2002238106A1 (en) 2001-02-13 2002-08-28 Palatin Technologies, Inc. Melanocortin metallopeptides for treatment of sexual dysfunction
JP4336196B2 (ja) * 2001-07-18 2009-09-30 メルク エンド カムパニー インコーポレーテッド メラノコルチン受容体作動薬としての架橋ピペリジン誘導体
WO2004005324A2 (fr) 2002-07-09 2004-01-15 Palatin Technologies, Inc. Composition peptidique pour le traitement de la dysfonction sexuelle
US11590209B2 (en) 2020-01-21 2023-02-28 Palatin Technologies, Inc. Use of bremelanotide in patients with controlled hypertension

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5962528A (en) * 1991-07-03 1999-10-05 Scott; Nathan Earl Prostaglandin E2 /F2α combination for treating impotence
DE69423533T2 (de) * 1993-02-10 2000-08-24 B.M.R.A. Corp. B.V., Rotterdam Zubereitungen zur Behandlung von Impotenz, die ein Alpha-1 inhibitor und ein Alpha-2 inhibitor enthalten
WO1994022460A1 (fr) * 1993-04-05 1994-10-13 University Patents, Inc. Diagnostic et traitement des dysfonctionnements erectiles
GB9311920D0 (en) * 1993-06-09 1993-07-28 Pfizer Ltd Therapeutic agents
GB9423911D0 (en) * 1994-11-26 1995-01-11 Pfizer Ltd Therapeutic agents
US5731339A (en) * 1995-04-28 1998-03-24 Zonagen, Inc. Methods and formulations for modulating the human sexual response
GB9514464D0 (en) * 1995-07-14 1995-09-13 Glaxo Lab Sa Medicaments
US5994294A (en) * 1996-02-02 1999-11-30 Nitromed, Inc. Nitrosated and nitrosylated α-adrenergic receptor antagonist compounds, compositions and their uses
US5932538A (en) * 1996-02-02 1999-08-03 Nitromed, Inc. Nitrosated and nitrosylated α-adrenergic receptor antagonist compounds, compositions and their uses
US6037346A (en) * 1997-10-28 2000-03-14 Vivus, Inc. Local administration of phosphodiesterase inhibitors for the treatment of erectile dysfunction
ES2258300T3 (es) * 1997-12-16 2006-08-16 Pfizer Products Inc. Combinacion de antagonistas del receptor alfa-1-adrenergico y un inhibidor gmpc pdev para el tratamiento de la impotencia.
CA2314369A1 (fr) * 1997-12-18 1999-06-24 Nathan Earl Scott Combinaison de prostaglandines e2/f2.alpha., destinee au traitement de l'impuissance et a l'accroissement de l'excitation sexuelle
GT199900061A (es) * 1998-05-15 2000-10-14 Pfizer Formulaciones farmaceuticas.
AU4068599A (en) * 1998-05-20 1999-12-06 Schering Corporation Combination of phentolamine and cyclic gmp phosphodiesterase inhibitors for the treatment of sexual dysfunction
US6124461A (en) * 1998-05-26 2000-09-26 Saint Louis University, Health Services Center, Research Administration Compounds, compositions, and methods for treating erectile dysfunction
US6200591B1 (en) * 1998-06-25 2001-03-13 Anwar A. Hussain Method of administration of sildenafil to produce instantaneous response for the treatment of erectile dysfunction
US6007824A (en) * 1998-07-09 1999-12-28 Duckett; Melvin J. Natural composition and method for the treatment of sexual dysfunction

Also Published As

Publication number Publication date
AU3724400A (en) 2000-09-28
EP1161255A4 (fr) 2002-07-17
EP1161255A2 (fr) 2001-12-12
WO2000053148A2 (fr) 2000-09-14
WO2000053148A3 (fr) 2000-12-14

Similar Documents

Publication Publication Date Title
AU704955B2 (en) Use of CGMP-phosphodiesterase inhibitors to treat impotence
AU2009324495B2 (en) Methods for treating multiple sclerosis using tetracyclic pyrazinoindoles
JPH0621070B2 (ja) ジアゼピン含有医薬組成物
IL98425A (en) Pharmacological preparations for the treatment of rejection of organ transplants, which contain the result of a converted quinoline
US5290783A (en) Use of spiperone derivatives as immunosuppressant agents
CA2362918A1 (fr) Procedes et compositions pour le traitement de la dyserection
KR100874815B1 (ko) 간질성 방광염 치료용 의약 조성물
AU5198301A (en) The use of growth hormone secretagogues to treat systemic lupus erythematosus and inflammatory bowel disease
KR20030027865A (ko) 성장 호르몬 분비촉진제를 포함하는 약학 조성물 및 키트
JPH07504915A (ja) ムスカリン拮抗物質投与による，哺乳動物の眼における眼内圧低下法
BG100093A (bg) Използване на индолови производни като 5нт1-агонисти
DE69933671T2 (de) Adenosin a1 antagonisten gegen männliche sterilität
KR20020025730A (ko) 운동과 병행한, 성장 호르몬 분비촉진제의 용도
JP2004508272A (ja) アセチルコリンエンハンサー
WO1995028177A1 (fr) Composition medicinale destinee a traiter la dyskinesie tardive et utilisation de ladite composition
JP2002293743A (ja) 食欲を刺激するかまたは増進させるための成長ホルモン分泌促進物質の使用
JPWO2005007191A1 (ja) 医薬組成物
WO2022192252A1 (fr) Utilisation de nadolol pour traiter la bronchopneumopathie chronique obstructive par blocage de la voie de l'arrestine-2
TWI907146B (zh) 3-[(苯並[d][1,3]二氧戊環-4-基)-氧基]-3-芳基丙胺類化合物在製備治療性功能障礙的藥物中的用途
RU2111749C1 (ru) Применение атипамезола для лечения мужской сексуальной импотенции
JPH11503721A (ja) ベンズアミド誘導体の新規用途
RU2761219C2 (ru) Терапевтическое средство от расстройств, связанных с употреблением алкоголя
AU2004260624A1 (en) Use of 3,7-diazabicyclo`3, 3,1 !nonane compounds for the treatment and/or prophylaxis of anti-arrhythmic events in male human patients
JPH09500646A (ja) アザスピランによるｈｉｖの治療法
JPH07503240A (ja) ３‐アリールインドールおよび１‐アリールインダゾール誘導体の精神病の治療のための使用

Legal Events

Date Code Title Description
FZDE Dead